Clinical Trial

Study of Tenofovir Alafenamide in HBV-Infected Pregnant Women

Recruiting Phase 4
View on ClinicalTrials.gov →
Record status
This record was last updated September 8, 2025 (before its estimated December 30, 2025 completion). Its status may not reflect the trial's current state.
Summary
The purpose of this study is to evaluate the pharmacokinetics, efficacy and safety of TAF in HBV-infected pregnant women.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2023-05-08.
Trial Details
NCT Number NCT05853718
Lead Sponsor First People's Hospital of Hangzhou
Conditions Chronic Hepatitis b, Tenofovir Alafenamide Fumarate
Enrollment 50 participants
Start Date 2021-05-06
Primary Completion 2025-12-30 (estimated)
Study Completion 2025-12-30 (estimated)
Updated on ClinicalTrials.gov 2025-09-08